The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Severe Cutaneous Adverse Reaction

약물에 의한 중증 피부반응

  • Yang, Min Suk (Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center) ;
  • Jung, Jae Woo (Drug Allergy Workgroup of the Korean Academy of Asthma Allergy and Clinical Immunology) ;
  • Kang, Hye-Ryun (Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center)
  • 양민석 (서울대학교 의학연구원 알레르기 및 임상면역연구소) ;
  • 정재우 (대한천식알레르기학회 약물알레르기워크그룹) ;
  • 강혜련 (서울대학교 의학연구원 알레르기 및 임상면역연구소)
  • Published : 2014.12.01
⟨ Previous Next ⟩

Abstract

Severe adverse cutaneous reactions (SCARs) include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Although recent advances in pharmacogenomics have revealed the association between specific human leukocyte antigens (HLAs) and certain drug-induced SCARs, such associations were found in a limited number of drug-associated SCARs and are not sufficient to explain many other drug-related SCARs. After introducing research on the HLA-restricted T cell response, the role of the T cell receptor in drug binding was emphasized and a new concept called "pharmacological interactions of drug with immune receptors" has been conceptualized over recent decades. Currently, many international and domestic collaborative consortia have been formed and should enable the phenotypic standardization of SCARs at the earliest practicable time to provide valuable insights into its pathogenesis and to find an ideal method to prevent patients from developing SCARs.

Keywords

References

  1. Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy 2012;97:149-166. https://doi.org/10.1159/000335627
  2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96. https://doi.org/10.1001/archderm.1993.01680220104023
  3. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013;13:60-69. https://doi.org/10.1038/tpj.2011.41
  4. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306. https://doi.org/10.1097/01.fpc.0000199500.46842.4a
  5. Yager JA. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review. Vet Dermatol 2014;25:406-e464. https://doi.org/10.1111/vde.12142
  6. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-129. https://doi.org/10.1097/ICO.0b013e31802eb264
  7. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-1244. https://doi.org/10.1007/s001340050492
  8. Yang MS, Kang MG, Jung JW, et al. Clinical features and prognostic factors in severe cutaneous drug reactions. Int Arch Allergy Immunol 2013;162:346-354. https://doi.org/10.1159/000354918
  9. Weinand C, Xu W, Perbix W, et al. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns 2013;39:1449-1455. https://doi.org/10.1016/j.burns.2013.03.011
  10. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010;94:645-664, xv. https://doi.org/10.1016/j.mcna.2010.04.003
  11. Camous X, Calbo S, Picard D, Musette P. Drug reaction with eosinophilia and systemic symptoms: an update on pathogenesis. Curr Opin Immunol 2012;24:730-735. https://doi.org/10.1016/j.coi.2012.07.010
  12. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol 2013;68:693e1-14; quiz 706-708. https://doi.org/10.1016/j.jaad.2013.01.033
  13. Kim DH, Koh YI. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Immunol Res 2014;6:216-221. https://doi.org/10.4168/aair.2014.6.3.216
  14. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-611. https://doi.org/10.1111/j.1365-2133.2006.07704.x
  15. Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy 2014;69:798-805. https://doi.org/10.1111/all.12410
  16. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127(3 Suppl):S60-66. https://doi.org/10.1016/j.jaci.2010.11.046
  17. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579. https://doi.org/10.1056/NEJMoa0706135
  18. Park WB, Choe PG, Song KH, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009;48:365-367. https://doi.org/10.1086/595890
  19. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486. https://doi.org/10.1038/428486a
  20. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-1133. https://doi.org/10.1056/NEJMoa1009717
  21. Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-197. https://doi.org/10.1016/j.eplepsyres.2011.08.010
  22. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-1143. https://doi.org/10.1056/NEJMoa1013297
  23. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;92:757-765. https://doi.org/10.1038/clpt.2012.189
  24. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139. https://doi.org/10.1073/pnas.0409500102
  25. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-307. https://doi.org/10.1097/FPC.0b013e32834282b8
  26. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567-3572. https://doi.org/10.1093/ndt/gfr060
  27. Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg 2014;33:10-16. https://doi.org/10.12788/j.sder.0058
  28. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol 2013;68:709e1-9; quiz 718-720. https://doi.org/10.1016/j.jaad.2013.01.032

Cited by

  1. Toxic epidermal necrolysis induced by deflazacort vol.4, pp.3, 2014, https://doi.org/10.4168/aard.2016.4.3.221
  2. Experience of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Regional Hospital: 70 Cases in 7 Years vol.92, pp.2, 2014, https://doi.org/10.3904/kjm.2017.92.2.171
  3. Screening of severe adverse drug reaction by electronic medical record search vol.6, pp.3, 2014, https://doi.org/10.4168/aard.2018.6.3.135
  4. Adverse drug reactions vol.62, pp.9, 2014, https://doi.org/10.5124/jkma.2019.62.9.472